5241642025-01-012025-03-315241642025-03-315241642024-03-315241642024-04-012025-03-315241642025-01-012025-03-31in-capmkt:OtherExpenses1Member5241642024-04-012025-03-31in-capmkt:OtherExpenses1Member5241642025-01-012025-03-31in-capmkt:ReportableSegments1Member5241642025-01-012025-03-31in-capmkt:ReportableSegments2Member5241642025-01-012025-03-31in-capmkt:ReportableSegments3Member5241642024-04-012025-03-31in-capmkt:ReportableSegments1Member5241642024-04-012025-03-31in-capmkt:ReportableSegments2Member5241642024-04-012025-03-31in-capmkt:ReportableSegments3Member5241642025-01-012025-03-31in-capmkt:ReportableSegments1Member5241642025-01-012025-03-31in-capmkt:ReportableSegments2Member5241642025-01-012025-03-31in-capmkt:ReportableSegments3Member5241642024-04-012025-03-31in-capmkt:ReportableSegments1Member5241642024-04-012025-03-31in-capmkt:ReportableSegments2Member5241642024-04-012025-03-31in-capmkt:ReportableSegments3Member5241642025-01-012025-03-31in-capmkt:ReportableSegments1Member5241642025-03-31in-capmkt:ReportableSegments1Member5241642025-01-012025-03-31in-capmkt:ReportableSegments2Member5241642025-03-31in-capmkt:ReportableSegments2Member5241642025-01-012025-03-31in-capmkt:ReportableSegments3Member5241642025-03-31in-capmkt:ReportableSegments3Member5241642025-01-012025-03-31in-capmkt:ReportableSegments1Member5241642025-03-31in-capmkt:ReportableSegments1Member5241642025-01-012025-03-31in-capmkt:ReportableSegments2Member5241642025-03-31in-capmkt:ReportableSegments2Member5241642025-01-012025-03-31in-capmkt:ReportableSegments3Member5241642025-03-31in-capmkt:ReportableSegments3Member5241642025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15241642024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15241642025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15241642024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15241642025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524164IOLCPNOTLISTEDINE485C01029IOL Chemicals and Pharmaceuticals LimitedMain BoardEquity2024-04-012025-03-312025-05-162025-05-06INRCroresQuarterlyFourth quarterMulti segment2025-05-1616:00:002025-05-1617:37:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated527780000045300000532310000034761000000-18200000523900000403000001855000006685000004876100000447000000044700000070600000622000001328000000314200000000031420000020000031440000058710000021.071.07001.071.07NOTES: 1.The above standalone and consolidated audited financial results for the quarter and year ended 31st March 2025 have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their meetings held on 16th May 2025. 2.The financial results of the Company have been audited by the Statutory Auditors and prepared in accordance with the Indian Accounting Standards Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and are in compliance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The Statutory Auditors have expressed an unmodified opinion on these results.3.As per Ind AS 108 Operating Segments, the Company has two reportable Operating Segments namely ‘Pharmaceuticals’ and ‘Chemicals’. The financial information for these segments has been provided in Financial Results.4.The Board of Directors, at their meeting held on 27th December 2024, approved the sub-division split of each equity share having a face value of Rs. 10 into five Equity Shares of face value of Rs.2 each, fully paid up. This sub division was subsequently approved by the shareholders through a Postal Ballot on 31st January 2025. The split became effective on both stock exchanges BSE and NSE from the record date, 11th March 2025. Accordingly, as required under Ind AS, the Company has presented basic and diluted earnings per share based on the revised number of shares for both the current and previous reporting periods.5.The figures for the quarter ended 31st March 2025 as reported in the standalone and consolidated financial results, are the balancing figures between the audited figures for the year ended 31st March 2025 and the published year to date figures for 31st December 2024, which were subjected to limited review by the statutory auditors.6.The previous financial period figures have been regrouped rearranged restated, wherever considered necessary.2024-04-012025-03-31AuditedConsolidated207921000002241000002101620000013583400000033510000021657000001476000007199000002684900000196366000001379600000013796000002474000001215000003689000000101070000000001010700000-144000009963000005871000002162895000003.443.44003.443.44Other Expenses668500000Other Expenses26849000001158370000020810000001234000001120000017410000007880000025290000012800000012307300000360620000033000000513690000078170000012998000000563000007307700000340000059610000011513400000238207000005871000001628950000016876600000168766000000066900000778100000845000000117040000067400000420820000042756000004625000005908500000170900000197000006099100000694410000023820700000Chemical2612400000Pharmaceutical3222700000Unallocated45400000Chemical10793900000Pharmaceutical12123200000Unallocated2243000005880500000231414000005575000002125200000532300000021016200000Chemical65200000Pharmaceutical409200000Unallocated0Chemical153900000Pharmaceutical1262700000Unallocated0474400000141660000040300000147600000-12900000-1106000004470000001379600000Chemical5348500000Pharmaceutical13817100000Unallocated465510000023820700000023820700000Chemical3001600000Pharmaceutical1948800000Unallocated1993700000694410000006944100000147600000642200000-390400000000000-4605000000007199000000000038800000010580000000000-2000000058980000019694000000001832000000178620000000000000980000021355000000000000000000000001233000000460600000-1541800000000000008428000000023480000014760000000460400000704800000070480000076900000781700000Remeasurement gain/(loss) of defined benefit obligation94000009400000Remeasurement gain/(loss) of defined benefit obligation-9700000-97000002400000-2400000Net movement in effective portion of cash flow hedge reserve-9100000-9100000Net movement in effective portion of cash flow hedge reserve-9500000-9500000-2300000-2400000200000-14400000AuditedtrueM/s Ashwani & Associatestrue2026-01-31